Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Precision BioSciences, Inc. - Common Stock (NQ:DTIL)

6.230 +0.030 (+0.48%)
Delayed Quote Updated: 1:01 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Precision BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
From Precision BioSciences, Inc.
Via Business Wire
News headline image
7 Biotech Stocks to Buy for Their Game-Changing Potential ↗
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
News headline image
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming August Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report Second Quarter Results on August 1, 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces its Addition to the Russell Microcap® Index
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Participate in Upcoming June Investor Conferences
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
News headline image
DTIL Stock Earnings: Precision BioSciences Beats EPS, Beats Revenue for Q1 2024 ↗
DTIL stock results show that Precision BioSciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences to Report First Quarter Results on May 13, 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
From Precision BioSciences
Via Business Wire
News headline image
Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024
From Precision BioSciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
From Precision BioSciences, Inc.
Via Business Wire
News headline image
DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023 ↗
DTIL stock results show that Precision BioSciences missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.